ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by reducing bradykinin production, potentially offering better and less frequent treatment than current options. The presentation will also cover the ongoing Phase 3 STOP-HAE trial, which aims to confirm these benefits. This therapy has received Orphan Drug Designation from the FDA, highlighting its potential to improve HAE management.
Clearfield cut its FY2026 guidance because of delays in broadband projects linked to slow government BEAD program rollout and fiber supply constraints. However, the company secured a $22 million order for hyperscale data centers, validating its growt...
Charles Schwab is expanding its Schwab Crypto platform by adding Solana, Avalanche, and Chainlink to its existing Bitcoin and Ethereum offerings. This move aims to provide investors with more options to build diverse digital asset portfolios while le...
Bitcoin traded near $79,771 after reaching an intraday high of $81,280 but failed to break decisively above the $82,000 resistance level. Veteran trader Peter Brandt disclosed a long Bitcoin position following a bullish inverse head-and-shoulders bre...
The HYPE token reached a new all-time high of $84.80 after a 40% weekly gain and breaking the $77 resistance. Hyperliquid Strategies increased its holdings to 29.3 million HYPE tokens following a $646.6 million capital raise. The company activated an...
Xiaomi will invest $29 billion in research and development between 2026 and 2030, prioritizing advancements in custom artificial intelligence, chips, and operating systems. This investment aims to strengthen its Human x Car x Home ecosystem and boost...
